We are live on ! Find out more
ACM

Aquilo Capital Management Portfolio holdings

AUM $55.8M
1-Year Est. Return 41.76%
This Fund
S&P 500
This Quarter Est. Return
+17.86%
1 Year Est. Return
-41.76%
3 Year Est. Return
-6.84%
5 Year Est. Return
+20.73%
10 Year Est. Return
–
AUM
$133M
AUM Growth
-$27M
Cap. Flow
-$49.8M
Cap. Flow %
-37.29%
Top 10 Hldgs %
100%
Holding
11
New
1
Increased
2
Reduced
5
Closed
1

Top Buys

Rank Stock Value
1
DTIL icon
Precision BioSciences
DTIL
+$4.72M
2
STRO icon
Sutro Biopharma
STRO
+$3.29M
3
RGNX icon
Regenxbio
RGNX
+$1.85M

Top Sells

Rank Stock Value
1
KYMR icon
Kymera Therapeutics
KYMR
+$17.6M
2
SLN
Silence Therapeutics
SLN
+$10.2M
3
BPMC
Blueprint Medicines
BPMC
+$6.23M
4
MRUS
Merus
MRUS
+$4.06M
5
ARVN icon
Arvinas
ARVN
+$3.64M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ARWR icon
1
Arrowhead Research
ARWR
$12.4B
$26M 19.47%
908,474
– –
RGNX icon
2
Regenxbio
RGNX
$708M
$19.1M 14.31%
906,248
+103,824
+13% +$1.85M
BPMC
3
DELISTED
Blueprint Medicines
BPMC
$17.3M 12.95%
182,151
-72,676
-29% -$6.23M
ARVN icon
4
Arvinas
ARVN
$572M
$16.8M 12.55%
405,766
-83,387
-17% -$3.64M
KYMR icon
5
Kymera Therapeutics
KYMR
$8.94B
$15.6M 11.71%
388,743
-492,594
-56% -$17.6M
SLN
6
Silence Therapeutics
SLN
$564M
$12.4M 9.3%
574,214
-469,070
-45% -$10.2M
MRUS
7
DELISTED
Merus
MRUS
$11.5M 8.61%
255,109
-100,000
-28% -$4.06M
STRO icon
8
Sutro Biopharma
STRO
$421M
$6.58M 4.94%
116,547
+74,482
+177% +$3.29M
DTIL icon
9
Precision BioSciences
DTIL
$207M
$5.23M 3.92%
+385,440
New +$4.72M
RPTX
10
DELISTED
Repare Therapeutics
RPTX
$2.98M 2.24%
633,271
– –
XBI icon
11
PUT
State Street SPDR S&P Biotech ETF
XBI
$10.3B
– –
-200,000
Closed -$17.9M

Similar funds

VCM
VeriStar Capital Management New York $54.7M AUM 2.08% 1-Year Est. Return
YEPV
Yorktown Energy Partners VIII New York $52.9M AUM 30% 1-Year Est. Return
HWP
Heritage Wealth Partners Dublin, Ohio $65.6M AUM 16.69% 1-Year Est. Return
GIS
Grayhawk Investment Strategies Calgary, Alberta, Canada $43.9M AUM 6.23% 1-Year Est. Return
AA
AlphaQ Advisors Winter Park, Florida $41.7M AUM 12.96% 1-Year Est. Return
PGIM
Pacific Global Investment Management Glendale, California $70.7M AUM 14.46% 1-Year Est. Return
RGMC
Revolution Growth Management Company Washington, District of Columbia $70.8M AUM 20.1% 1-Year Est. Return
PAM
Pamalican Asset Management Hong Kong $75.4M AUM

Aquilo Capital Management's Q1 2024 Portfolio in Review

As of Q1 2024, Aquilo Capital Management held 11 positions worth $133M, down 17% from $160M the previous quarter. Its ten largest holdings account for 100% of the portfolio.

Aquilo Capital Management withdrew a net $49.8M in Q1 2024, closing 1 position and reducing 5 holdings. Its largest reduction was Kymera Therapeutics, cutting an estimated $17.6M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 89% a quarter earlier.

Against the trend, Aquilo Capital Management opened a new position in Precision BioSciences worth $5.23M.

  • Aquilo Capital Management's largest Q1 2024 buy was Precision BioSciences: 385,440 shares worth $5.23M.
  • Aquilo Capital Management added most to Sutro Biopharma in Q1 2024, an estimated $3.29M increase.
  • Aquilo Capital Management's biggest Q1 2024 reduction was Kymera Therapeutics, cutting an estimated $17.6M.
  • Aquilo Capital Management's ten largest holdings make up 100% of its $133M portfolio in Q1 2024.
  • Aquilo Capital Management opened 1 new position and closed 1 in Q1 2024.
  • Aquilo Capital Management's portfolio value fell 17% quarter-over-quarter to $133M.

Based on Aquilo Capital Management's 13F filing for Q1 2024, filed 15 May 2024.